In fiscal 2026, which ended Apr 24, 2026, Medtronic plc reported revenue of $36.4 billion, up 8.4% from the year before. Net income was $4.8 billion, a profit margin of 13.2%. Operating income came to $6.5 billion, an operating margin of 17.8%. Diluted earnings per share were $3.73. Over the twelve months ended Jul 31, 2026, revenue was $37.5 billion and net income was $5.2 billion. Across the 10 fiscal years shown, revenue grew from $29.7 billion in fiscal 2017 to $36.4 billion in fiscal 2026, about 2.3% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2027
Jul 31, 2026
|
FY 2026
Apr 24, 2026
|
FY 2025
Apr 25, 2025
|
FY 2024
Apr 26, 2024
|
FY 2023
Apr 28, 2023
|
FY 2022
Apr 29, 2022
|
FY 2021
Apr 30, 2021
|
FY 2020
Apr 24, 2020
|
FY 2019
Apr 26, 2019
|
FY 2018
Apr 27, 2018
|
FY 2017
Apr 28, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
37,542
+9.8%
|
36,364
+8.4%
|
33,537
+3.6%
|
32,364
+3.6%
|
31,227
-1.4%
|
31,686
+5.2%
|
30,117
+4.2%
|
28,913
-5.4%
|
30,557
+2.0%
|
29,953
+0.8%
|
29,710
+3.0%
|
| Cost of revenue |
13,136
+10.6%
|
12,721
+9.4%
|
11,632
+3.7%
|
11,216
+4.6%
|
10,719
+5.7%
|
10,145
-3.2%
|
10,483
+11.2%
|
9,424
+2.9%
|
9,155
+1.0%
|
9,067
-2.4%
|
9,294
+1.7%
|
| Gross profit |
24,406
+9.3%
|
23,643
+7.9%
|
21,905
+3.6%
|
21,148
+3.1%
|
20,508
-4.8%
|
21,541
+9.7%
|
19,634
+0.7%
|
19,489
-8.9%
|
21,402
+2.4%
|
20,898
+2.3%
|
20,419
+3.7%
|
| Selling, general and administrative |
12,176
+10.7%
|
11,784
+8.6%
|
10,849
+1.1%
|
10,736
+3.1%
|
10,415
+1.2%
|
10,292
+1.4%
|
10,148
+0.4%
|
10,109
-3.0%
|
10,418
+1.8%
|
10,238
+2.2%
|
10,018
+5.8%
|
| Other operating income (expense) |
-439
-854.3%
|
-386
-1778.3%
|
23
+105.0%
|
-464
-454.2%
|
131
+115.2%
|
-862
-173.7%
|
-315
-343.7%
|
-71
+72.5%
|
-258
|
—
|
—
|
| Operating income |
6,786
+10.8%
|
6,467
+8.6%
|
5,955
+15.8%
|
5,144
-6.2%
|
5,485
-4.6%
|
5,752
+28.3%
|
4,484
-6.4%
|
4,791
-23.6%
|
6,268
-5.6%
|
6,640
+23.4%
|
5,383
+0.4%
|
| Interest expense |
725
-1.8%
|
715
-1.9%
|
729
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Other non-operating income (expense) |
541
+94.6%
|
384
-4.5%
|
402
-2.4%
|
412
-20.0%
|
515
+61.9%
|
318
-5.4%
|
336
-5.6%
|
356
-4.6%
|
373
|
—
|
—
|
| Pretax income |
6,603
+16.6%
|
6,136
+9.0%
|
5,628
+16.4%
|
4,837
-9.8%
|
5,364
-2.8%
|
5,517
+41.6%
|
3,895
-3.9%
|
4,055
-22.0%
|
5,197
-8.4%
|
5,675
+23.3%
|
4,602
+6.1%
|
| Income tax |
1,333
+37.3%
|
1,299
+38.8%
|
936
-17.4%
|
1,133
-28.3%
|
1,580
+246.5%
|
456
+72.1%
|
265
+135.3%
|
-751
-237.3%
|
547
-78.8%
|
2,580
+346.4%
|
578
-27.6%
|
| Net income |
5,231
+12.3%
|
4,801
+3.0%
|
4,662
+26.8%
|
3,676
-2.2%
|
3,758
-25.4%
|
5,039
+39.7%
|
3,606
-24.7%
|
4,789
+3.4%
|
4,631
+49.2%
|
3,104
-22.9%
|
4,028
+13.8%
|
| Basic EPS |
4.08
+12.4%
|
3.75
+3.3%
|
3.63
+31.0%
|
2.77
-2.1%
|
2.83
-24.5%
|
3.75
+39.9%
|
2.68
-24.9%
|
3.57
+3.8%
|
3.44
+50.2%
|
2.29
-21.6%
|
2.92
+16.3%
|
| Diluted EPS |
4.06
+12.3%
|
3.73
+3.3%
|
3.61
+30.8%
|
2.76
-2.1%
|
2.82
-24.4%
|
3.73
+40.2%
|
2.66
-24.9%
|
3.54
+3.8%
|
3.41
+50.2%
|
2.27
-21.5%
|
2.89
+16.5%
|
| Weighted average shares, basic |
1,281
-0.1%
|
1,282
-0.3%
|
1,286
-3.2%
|
1,328
-0.2%
|
1,330
-0.9%
|
1,342
-0.2%
|
1,345
+0.3%
|
1,341
-0.4%
|
1,346
-0.8%
|
1,357
-1.6%
|
1,379
-2.2%
|
| Weighted average shares, diluted |
1,288
-0.0%
|
1,288
-0.1%
|
1,290
-3.0%
|
1,330
-0.2%
|
1,333
-1.4%
|
1,351
-0.2%
|
1,354
+0.2%
|
1,351
-0.5%
|
1,358
-0.8%
|
1,368
-1.7%
|
1,391
-2.4%
|
| Other measures | |||||||||||
| Depreciation and amortization |
2,939
-0.3%
|
2,958
+3.4%
|
2,861
+8.1%
|
2,647
-1.9%
|
2,697
-0.4%
|
2,707
+0.2%
|
2,702
+1.5%
|
2,663
+0.2%
|
2,659
+0.6%
|
2,644
-9.4%
|
2,917
+3.4%
|
| EBITDA |
9,725
+7.2%
|
9,425
+6.9%
|
8,816
+13.2%
|
7,791
-4.8%
|
8,182
-3.3%
|
8,459
+17.7%
|
7,186
-3.6%
|
7,454
-16.5%
|
8,927
-3.8%
|
9,284
+11.9%
|
8,300
+1.5%
|
| Interest coverage |
9.36x
|
9.04x
|
8.17x
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Margins | |||||||||||
| Gross margin |
65.01%
|
65.02%
|
65.32%
|
65.34%
|
65.67%
|
67.98%
|
65.19%
|
67.41%
|
70.04%
|
69.77%
|
68.73%
|
| Operating margin |
18.08%
|
17.78%
|
17.76%
|
15.89%
|
17.56%
|
18.15%
|
14.89%
|
16.57%
|
20.51%
|
22.17%
|
18.12%
|
| Pretax margin |
17.59%
|
16.87%
|
16.78%
|
14.95%
|
17.18%
|
17.41%
|
12.93%
|
14.02%
|
17.01%
|
18.95%
|
15.49%
|
| Profit margin |
13.93%
|
13.20%
|
13.90%
|
11.36%
|
12.03%
|
15.90%
|
11.97%
|
16.56%
|
15.16%
|
10.36%
|
13.56%
|
| EBITDA margin |
25.90%
|
25.92%
|
26.29%
|
24.07%
|
26.20%
|
26.70%
|
23.86%
|
25.78%
|
29.21%
|
31.00%
|
27.94%
|
| Effective tax rate |
20.19%
|
21.17%
|
16.63%
|
23.42%
|
29.46%
|
8.27%
|
6.80%
|
-18.52%
|
10.53%
|
45.46%
|
12.56%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- MDT (NYSE)
- Fiscal year ends
- April 24
- Headquarters
- Galway
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1613103
- Former names
- Medtronic Ltd (until Jan 15, 2015); Medtronic Holdings Ltd (until Nov 21, 2014)
Other Electromedical & Electrotherapeutic Apparatus companies
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
- CapsoVision, Inc CV
All 31 Electromedical & Electrotherapeutic Apparatus companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.